UPDATES!
$Immutep (IMMP.US)$ Immutep’s latest clinical trial, TACTI-003, shows promising results for its novel immunotherapy, efti, when combined with KEYTRUDA in treating head and neck cancer, with significantly improved response rates, notably in patients with high PD-L1 expression. The combination therapy not only proved to be efficacious but also maintained a favorable safety profile, demonstrating a potential new avenue for cancer treatment without compromising patient safety.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment